A family with serum cholinesterase (SC hE) deficiency is reported. A 64-year-old womanwas admitted for the excision of colon adenoma: chain reaction (PCR) and analyzed by d her laboratory data revealed amarkedly decreased level ofSChE. SChEgenes ofthe patient and her family memberswere amplified by the polymerase rect sequencing. The patient's SChEgene had a homozygous frame shift mutation, in which an extra adenine was inserted in codon 315 (ACC^AACC),resulting in the appearance of a new stop codon in codon 322. The family study disclosed that her brother and sister had the same frame shift mutations in homozygote and heterozygote, respectively. (Internal Medicine 34: 632-635, 1995) 
Introduction
Hereditary serum cholinesterase (SChE) deficiency is a rare disease that was first described by Kalow and Genest in 1957 (1) . There are no serious complications with this disease, however prolonged postoperative succinylcholine-induced apnea does develop. Recently several types of SChEdeficiency have been distinguished by the differences in abnormalities in the SChEgene. Some patients were found to have point mutations in the SChE gene. Herein, we report a patient with decreased SChE which was incidentally identified, and the results of gene analysis of her family members.
Case Report
A 64-year-old womanwas admitted to our hospital for removal of a polyp of the colon by endoscopic polypectomy. Laboratory data incidentally revealed that the level of SChE was markedly decreased. On physical examination, the general condition of the patient appeared to be fair. She was not emaciated (height 1 52 cm; weight 47 kg) and her blood pressure was 140/70 mmHg.The pulse rate was 78/min and regular. Examination of the chest, abdomen, and nervous system revealed no abnormal findings. Table 1 shows the laboratory data on admission. She had been diagnosed as diabetes mellitus 9 years earlier, but had not been treated. Urinalysis was positive for sugar. Biochemical tests indicated increased levels of fasting blood sugar (FBS) and hemoglobin AiC (HbA^), and an unusually low level of SChE. No other abnormalities were found in the biochemical tests including liver function tests and Indocyanine green tests. On both ultrasonography and computed tomography, the liver was normal and had no malignant tumors. She had no previous history of organophosphate compound poisoning. SChE studies carried out on her family members indicated that the patient' s younger brother, younger sister and niece were suspected of having the SChEdeficiency (Fig.1 ).
Methods and Results
Determination of SChEactivity Wedetermined the SChE activity of the patient's family by two different methods using the substances of benzoylcholine (BzCh) and bathyryl-thiocholine (BtSCh). The patient (II-l) and her younger brother (II-2) had unusually low SChE activity, but her younger sister (II-3) and her niece (III-3) were showed a normal level ( Table 2 ). An inhibition assay was also performed according to the method of Iuchi and Ameno (2) to determine the inhibition numbers, dibucaine-number (DN) and fluoride-number (FN). However, the inhibition numbers of the patient and her younger brother could not be measured, since the SChEactivities were too low to be determined.
SChEenzyme anaiysis by electrophoresis Isozyme fractionation of SChEwas analyzed by polyaerylamide gel electrophoresis. SChEisozymes of the normal serum were resolved into at least four bands, Cl to C4, while no isozyme bands were detected in the sera of the patient (II-1) and her younger brother (II-2) (Fig. 2) . Anti-human SChE rabbit serum purchased from DAKO(Glostrup, Denmark) was used as the first antibody for Western Blotting analysis to identify the bands of normal serum were stained with a substrate solution containing diaminobenthidine, H2O2, and NiCl2. However, no SChE protein band could be found in the sera of the patient (II-1) or her younger brother (II-2). Both isozyme bands and immunoreactive protein bands were identified for the serum of the younger sister of the patient (II-3), but the intensity of the bands was much weaker than that of normal serum (data not shown).
Analysis of the DNAof the patient's family Since neither the enzymeactivity or immunoreactive protein of SChEwas detected in the patient's serum, an abnormality at the gene level was suspected. Thus the nucleotide sequence of the SChE silent gene was analyzed and compared among four individuals of the patient's family. The DNAof the four individuals was extracted from peripheral white blood cells and amplified by 35 cycles of polymerase chain reaction (PCR) according to the method of Saiki, et al (3) . Twoamplification primer sets labeled with 32P were used for the PCRmethod. The PCRproducts were processed for the direct sequencing by the dideoxy chain termination method and analyzed by polyacrylamide gel electrophoresis (Fig. 3) . Sequence analysis revealed that DNAof both the patient (II-1) and her younger brother (II-2) had a frame shift mutation in the SChEsilent gene, in which an extra A was inserted in codon 3 15 (ACC-^AACC) to result in the appearance of a stop codon (TAA)in codon 322. The same frame shift mutation was identified in the sequence of her younger sister (II-3). However since no double base band was detected in the two individuals but was detected at three nucleotide positions of codons 315 and 316, the frame shift mutation was concluded to be homozygous for the two individuals and heterozygous for the younger sister. Her niece (III-3) was normal.
Discussion
SChE is thought to be produced by the liver-cells and the activity of SChEis widely used as a parameter of protein synthesis in the liver. The reduction of SChEactivity can be caused by the inheritance of an abnormal gene without liver diseases, malignant tumor, or organophosphate compoundpoisoning. Patients with SChEdeficiency have no symptoms in daily life except for prolonged postoperative apnea due to succinylcholine (4) (5) (6) . Several cases that were found incidentally by blood chemistry examination have been reported (7) (8) (9) (12) . A point mutation was found in codon 365 (GGA^CGA) in one case. In the other cases heterozygous double mutations were found in both codon 365 (GGA->CGA) and codon 315 (ACC^AACC), the latter of which leads to a frame shift mutation. We found that the present patient (II-1) and her younger brother (II-2) had the homozygous frame shift mutation in codon 3 15 (ACC->AACC), and that her younger sister had the same frame shift mutation in heterozygote. Although there are some differences in the zygosity, the findings of all cases reported here corresponded to those of the cases reported by Hidaka, et al (12) . Since the frame shift mutation results in the appearance of a newstop codon in codon 322, the almost complete lack of enzyme activity and absence of immunoreactive protein in the present cases (II-1 and II-2) are considered to be a result of the absence of production of SChEdue to the stop codon.
SChEdeficiency is not fatal and the patients have no symptoms in their daily lives. Therefore it is likely that there are many latent patients with abnormal SChEvariants, who might be incidentally discovered by gene analysis in the future.
